Yohann Loriot, MD, PhD, Gustave Roussy Institute, Villejuif, France, summarises the key finding of the trials DANUBE (NCT02516241), KEYNOTE-361 (NCT02853305) and JAVELIN Bladder 100 study (NCT02603432) which explored treatment options in urothelial cancer. The DANUBE trial concluded that a combination of durvalumab with tremelimumab is not more efficient than standard chemotherapy. Likewise, the KEYNOTE-361 trial showed that chemotherapy with durvalumab was not more efficient than chemotherapy alone either. The JAVELIN study provides promising evidence that avelumab benefits patients undergoing chemotherapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).